US.BSX · Boston Scientific

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.539568345323741,
        "turnoverUsdM": 663.6340509099999,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BSX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 47.7892,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 7.1,
      "take_profit_price": 54.3426,
      "target_multiplier": 1.6,
      "technical_strength": 1.5,
      "take_profit_percent": 5.7
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 7.079136690647482,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 68.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 64.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 47.811,
    "ma50": 46.2632,
    "close": 51.43,
    "prevClose": 51.83,
    "avgVolume20": 20277772,
    "volumeRatio": 0.64,
    "changePercent": -0.77
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": 0.01922314704716599,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.6359891044864764,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.4961786928143735,
      "volat_points": 0,
      "day_range_pct": 0.01604120163328793,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 68.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 15.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 78,
        "contribution": 15.6
      },
      {
        "raw": 11.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 78.67,
        "contribution": 11.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.9,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 59,
        "contribution": 5.9
      },
      {
        "raw": 20.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 68,
        "contribution": 20.4
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 64.3,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 15.6/20分",
      "市場環境分析總分: 11.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.9/10分",
      "技術信號分析總分: 20.4/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 15.6,
      "市場環境": 11.8,
      "情緒分析": 4,
      "技術信號": 20.4,
      "風險管理": 5.9
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.75,
          "roePoints": 0.4,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 663.6340509099999,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 4,
          "obvPoints": 3.2,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BSX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.25
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 705.8159980000001,
                "ma50": 712.735402,
                "name": "QQQ",
                "close": 729.87,
                "points": 1.4
              },
              "spy": {
                "ma20": 757.7255032499999,
                "ma50": 749.238004,
                "name": "SPY",
                "close": 772.66998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.539568345323741,
          "atrPoints": 2,
          "cciPoints": 4,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 4,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141226752,
                "url": "https://finnhub.io/api/news?id=195ffcf841a4fdcaf6d5cebab2fc8c58b2a5d070c8f44d4fb9688334ada279a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2.0b. The completed buyback represents 2.69% of the company’s shares. This update provides an additional data point on how Boston Scientific is allocating capital and managing its share count. It also offers a clearer backdrop for assessing recent stock performance and earnings expectations. See...",
                "category": "company",
                "datetime": 1786770483,
                "headline": "Boston Scientific (BSX), What Is Behind The Latest Investor Attention?"
              },
              {
                "id": 141226753,
                "url": "https://finnhub.io/api/news?id=4621fb65a45c2a5eba53503487e46440203bebae0adb9720ab7a849f5846763d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic sales growth guidance. Although the CHAMPION-AF trial met all clinical endpoints, it did not act as a meaningful catalyst for the business outlook, and the contrast between bullish...",
                "category": "company",
                "datetime": 1786763879,
                "headline": "Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?"
              },
              {
                "id": 141226754,
                "url": "https://finnhub.io/api/news?id=335f07356fadea9e75b71e544f82b09afccbb5f9f384f4e075463e6b62b86f4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trading below what the fundamentals imply. That gap between weak recent returns and an undervalued read is now front of mind for anyone looking at the current US$51.83 share price. Over the last 12 months, Boston Scientific has declined 49.8%, which puts recent investor sentiment and the current...",
                "category": "company",
                "datetime": 1786745604,
                "headline": "Is Boston Scientific (BSX) Still Undervalued After A 50% Fall?"
              },
              {
                "id": 141226755,
                "url": "https://finnhub.io/api/news?id=55433c80e75ebad19a7caab3efa90c342dfe578b4bba7b22720af19821500a42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500’s 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as […]",
                "category": "company",
                "datetime": 1786703082,
                "headline": "Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses"
              },
              {
                "id": 141206676,
                "url": "https://finnhub.io/api/news?id=7abea3ccfe08377481fd5e0f37f8dec44b691a75bc8a1a729baa8f037ed84ee9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
                "category": "company",
                "datetime": 1786627802,
                "headline": "Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet"
              },
              {
                "id": 141205638,
                "url": "https://finnhub.io/api/news?id=ebfa5769075e97a602a52fd7b83cec2836f85d750cb243af63d561c81837cfec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, […]",
                "category": "company",
                "datetime": 1786626893,
                "headline": "Here’s What Hurt Boston Scientific Corporation (BSX) in Q2"
              },
              {
                "id": 141192503,
                "url": "https://finnhub.io/api/news?id=0114c384af13db6c4685092791adbeee5212fb41eea7679e4dc19a14f358a711",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) screens as a decent value: cheap vs peers, strong profitability, and solid health, scoring 7/10.",
                "category": "company",
                "datetime": 1786535532,
                "headline": "Boston Scientific (NYSE:BSX) Screens as a Decent Value with Strong Fundamentals"
              },
              {
                "id": 141177697,
                "url": "https://finnhub.io/api/news?id=9396abdbc93d95b1c27ae12695ad453097f8a25c09cef1f2c13f8060f0a01d44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year.",
                "category": "company",
                "datetime": 1786385641,
                "headline": "Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?"
              }
            ],
            "raw_source": [
              {
                "id": 141241353,
                "url": "https://finnhub.io/api/news?id=5cab7b64c6cb8a72df1dc0efe8e960408190bd0370051d4d03bf5fa7cdf53c87",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.54% on an annualized basis producing an average annual return of 15.01%. Currently, Boston Scientific has a market capitalization of",
                "category": "company",
                "datetime": 1786964464,
                "headline": "If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141226752,
                "url": "https://finnhub.io/api/news?id=195ffcf841a4fdcaf6d5cebab2fc8c58b2a5d070c8f44d4fb9688334ada279a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2.0b. The completed buyback represents 2.69% of the company’s shares. This update provides an additional data point on how Boston Scientific is allocating capital and managing its share count. It also offers a clearer backdrop for assessing recent stock performance and earnings expectations. See...",
                "category": "company",
                "datetime": 1786770483,
                "headline": "Boston Scientific (BSX), What Is Behind The Latest Investor Attention?"
              },
              {
                "id": 141226753,
                "url": "https://finnhub.io/api/news?id=4621fb65a45c2a5eba53503487e46440203bebae0adb9720ab7a849f5846763d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic sales growth guidance. Although the CHAMPION-AF trial met all clinical endpoints, it did not act as a meaningful catalyst for the business outlook, and the contrast between bullish...",
                "category": "company",
                "datetime": 1786763879,
                "headline": "Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?"
              },
              {
                "id": 141226754,
                "url": "https://finnhub.io/api/news?id=335f07356fadea9e75b71e544f82b09afccbb5f9f384f4e075463e6b62b86f4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trading below what the fundamentals imply. That gap between weak recent returns and an undervalued read is now front of mind for anyone looking at the current US$51.83 share price. Over the last 12 months, Boston Scientific has declined 49.8%, which puts recent investor sentiment and the current...",
                "category": "company",
                "datetime": 1786745604,
                "headline": "Is Boston Scientific (BSX) Still Undervalued After A 50% Fall?"
              },
              {
                "id": 141226765,
                "url": "https://finnhub.io/api/news?id=944238222c9a941c04cbf9bb360c8aaf00f754e3da0e49ccc10edebf065198f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.",
                "category": "company",
                "datetime": 1786721820,
                "headline": "Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?"
              },
              {
                "id": 141216128,
                "url": "https://finnhub.io/api/news?id=65bf5a20ca49fa677ed91b73d8243709c5f98aa21cfb6e399a4d084fa22e6884",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session.",
                "category": "company",
                "datetime": 1786710901,
                "headline": "Get insights into the top movers in the S&P500 index of Friday's pre-market session."
              },
              {
                "id": 141216725,
                "url": "https://finnhub.io/api/news?id=75b3ea82141ce5c2d9b288a912788b857b5a70b3f29d76f59065d6a21564acbb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1282122168/image_1282122168.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why it’s a Buy—new launches, insider buying, cost savings.",
                "category": "company",
                "datetime": 1786705872,
                "headline": "Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead"
              },
              {
                "id": 141226755,
                "url": "https://finnhub.io/api/news?id=55433c80e75ebad19a7caab3efa90c342dfe578b4bba7b22720af19821500a42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500’s 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as […]",
                "category": "company",
                "datetime": 1786703082,
                "headline": "Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses"
              },
              {
                "id": 141210844,
                "url": "https://finnhub.io/api/news?id=2bf736f8c82a4e2be8402c591dd67c6328e0044a4c9301341ce2ff92fa7cc5f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.",
                "category": "company",
                "datetime": 1786656117,
                "headline": "How Much More Can Boston Scientific Stock Move After Losing Half Its Value?"
              },
              {
                "id": 141206676,
                "url": "https://finnhub.io/api/news?id=7abea3ccfe08377481fd5e0f37f8dec44b691a75bc8a1a729baa8f037ed84ee9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
                "category": "company",
                "datetime": 1786627802,
                "headline": "Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet"
              },
              {
                "id": 141205638,
                "url": "https://finnhub.io/api/news?id=ebfa5769075e97a602a52fd7b83cec2836f85d750cb243af63d561c81837cfec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, […]",
                "category": "company",
                "datetime": 1786626893,
                "headline": "Here’s What Hurt Boston Scientific Corporation (BSX) in Q2"
              },
              {
                "id": 141205611,
                "url": "https://finnhub.io/api/news?id=dd5eca2ade8f4181ead20a9e255e7c1a5afce1573708bd3d80f4816f41e5a7fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.",
                "category": "company",
                "datetime": 1786625460,
                "headline": "Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation"
              },
              {
                "id": 141205552,
                "url": "https://finnhub.io/api/news?id=8d6f1220353ab322d745ae83b3fe05b60386f09680f005e4e5b42c473a87a446",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.",
                "category": "company",
                "datetime": 1786625340,
                "headline": "What's Backing Abbott's Established Pharmaceuticals Division Growth"
              },
              {
                "id": 141192503,
                "url": "https://finnhub.io/api/news?id=0114c384af13db6c4685092791adbeee5212fb41eea7679e4dc19a14f358a711",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) screens as a decent value: cheap vs peers, strong profitability, and solid health, scoring 7/10.",
                "category": "company",
                "datetime": 1786535532,
                "headline": "Boston Scientific (NYSE:BSX) Screens as a Decent Value with Strong Fundamentals"
              },
              {
                "id": 141183707,
                "url": "https://finnhub.io/api/news?id=ab0b084a3da83dbf522e95924a06dfe2aee0bb0e46425b5469a1783b0a5b9f5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Pulsed Field Ablation Market Pulsed Field Ablation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players - Trends and Forecast till 2035\" has been added to ResearchAndMarkets.com's offering. The global pulsed field ablation market is projected to expand from approximately USD 3.2 billion in 2026 to USD 14.6 billion by 2035, re",
                "category": "company",
                "datetime": 1786439100,
                "headline": "Pulsed Field Ablation Global Market Report 2026 Now Available - Profiles Boston Scientific, Medtronic, Biosense Webster, and 15 Other Players"
              },
              {
                "id": 141183503,
                "url": "https://finnhub.io/api/news?id=6ed79ced93875335a1316f414b4c19e012f6139864424475b9652c0a22bc3221",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303046106/image_1303046106.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "The portfolio underperformed the MSCI All Country World Index during Q2. Read more here.",
                "category": "company",
                "datetime": 1786425000,
                "headline": "Artisan Global Equity Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 141182189,
                "url": "https://finnhub.io/api/news?id=1cad4b9aee05e58e83be10e3ef4b912db493ef6459ad80f2f634c89fcb89b9f8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2172700619/image_2172700619.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Despite U.S. growth headwinds for WATCHMAN and electrophysiology, Boston Scientific delivered strong Q2 2026 results. Read why BSX stock is a Strong Buy.",
                "category": "company",
                "datetime": 1786411256,
                "headline": "Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone"
              },
              {
                "id": 141177545,
                "url": "https://finnhub.io/api/news?id=900a27fb3b4f315b53cc3d81f4180c5a0e7c3de6b57840523330bdfb92cad3d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.",
                "category": "company",
                "datetime": 1786385693,
                "headline": "Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company"
              },
              {
                "id": 141177697,
                "url": "https://finnhub.io/api/news?id=9396abdbc93d95b1c27ae12695ad453097f8a25c09cef1f2c13f8060f0a01d44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year.",
                "category": "company",
                "datetime": 1786385641,
                "headline": "Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?"
              },
              {
                "id": 141176758,
                "url": "https://finnhub.io/api/news?id=0df65dc4336ad1d14fe4b1d3faed83033d4556aa1f2bdf26da7651c9edff9eaa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Mahoney expanded his equity stake by 13% following a -54% one-year stock decline. His combined holdings now total ~1.6 million shares valued at $78.08 million.",
                "category": "company",
                "datetime": 1786383961,
                "headline": "Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?"
              },
              {
                "id": 141175374,
                "url": "https://finnhub.io/api/news?id=a3d9ed08f889ac02696e8498896d72075f4866a254163fe724d8755d0b716d52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution.",
                "category": "company",
                "datetime": 1786372980,
                "headline": "Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?"
              },
              {
                "id": 141154791,
                "url": "https://finnhub.io/api/news?id=216a6f778ced1b977c924507815e48b2c461fa0608fa3746c55071f0043f91a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "WATCHMAN and Electrophysiology headwinds force guidance cut despite solid organic growth.",
                "category": "company",
                "datetime": 1786148065,
                "headline": "Boston Scientific (BSX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141151150,
                "url": "https://finnhub.io/api/news?id=32d5b9519615948dcf822d8231f5c8546a3160c8d5c642ad8d055909f90262fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products. Product safety questions can prompt...",
                "category": "company",
                "datetime": 1786129779,
                "headline": "What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?"
              },
              {
                "id": 141140693,
                "url": "https://finnhub.io/api/news?id=2abfcad6ab1aeb4d23fee77ebc3b71c6f2315c4847e5205beeed268299b0a665",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.",
                "category": "company",
                "datetime": 1786040160,
                "headline": "Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?"
              },
              {
                "id": 141140621,
                "url": "https://finnhub.io/api/news?id=5a6f32da6a1cb9c37b31b91ca6a1ad5265594dafcc9d698d08129586c01086e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.",
                "category": "company",
                "datetime": 1786039980,
                "headline": "ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus"
              },
              {
                "id": 141140622,
                "url": "https://finnhub.io/api/news?id=0e1174f6ba0b007d3383ae931962246e360ffe9b2d45e970b684a4bbf165f2e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.",
                "category": "company",
                "datetime": 1786039620,
                "headline": "ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?"
              },
              {
                "id": 141135534,
                "url": "https://finnhub.io/api/news?id=e587e417ff17f1c9de001d7a7f49dbe4c620ff53f6978304c2295dd28035c946",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.",
                "category": "company",
                "datetime": 1786027080,
                "headline": "Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test"
              },
              {
                "id": 141132291,
                "url": "https://finnhub.io/api/news?id=a4be55e268c5a2f7a9605bc2cc25490523542cfe4ce6f261641d0211a5aa0a3c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1421629295/image_1421629295.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "The Fund generated a net return of +15.24% during the second quarter, underperforming the Russell 1000 Growth Index return of +16.74%. Read more here.",
                "category": "company",
                "datetime": 1785988800,
                "headline": "TCW Concentrated Large Cap Growth Fund Q2 2026 Portfolio Update"
              },
              {
                "id": 141126827,
                "url": "https://finnhub.io/api/news?id=0c31fe0b2d0caab81d508e5fdaea005a58287c2047d6405ce71ba4ef83761794",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.",
                "category": "company",
                "datetime": 1785963901,
                "headline": "Stay updated with the S&P500 stocks that are on the move in today's after-hours session."
              },
              {
                "id": 141125706,
                "url": "https://finnhub.io/api/news?id=323e5a3f9c5dd535eafdd88ad8552039eeecd9956c9b18925cca11db56bff5ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain.",
                "category": "company",
                "datetime": 1785958260,
                "headline": "Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy."
              },
              {
                "id": 141124190,
                "url": "https://finnhub.io/api/news?id=ef66cdca1edae98df18b0c5ebc62b1879e71fd41b3c066690822a1c935a99bcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.",
                "category": "company",
                "datetime": 1785945060,
                "headline": "Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?"
              },
              {
                "id": 141124382,
                "url": "https://finnhub.io/api/news?id=fc705492de56e8315f6b3477affb9c62b6b32f449330781b328a2b17247dac75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Despite nearly doubling revenues to $21+ billion in the past 5 years, BSX has dropped 60% in the past year",
                "category": "company",
                "datetime": 1785942120,
                "headline": "Bear of the Day: Boston Scientific (BSX)"
              },
              {
                "id": 141108783,
                "url": "https://finnhub.io/api/news?id=0a731f87fad645ec97804e6ea04a4bce078092c61a06a7cd52cb0144dfd9626e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1785845602,
                "headline": "2 Profitable Stocks to Keep an Eye On and 1 We Turn Down"
              },
              {
                "id": 141105748,
                "url": "https://finnhub.io/api/news?id=09adccb8613d49ea51a4b96a3ceb52f388354fa11b297b41e2a7bf175eae0193",
                "image": "",
                "source": "Fintel",
                "related": "BSX",
                "summary": "",
                "category": "company",
                "datetime": 1785818020,
                "headline": "Boston Scientific (BSX) Price Target Decreased by 14.59% to 68.21"
              },
              {
                "id": 141100908,
                "url": "https://finnhub.io/api/news?id=e4fb0ac9dbc8e8ca0df683b11a60daf97614e17b5f0f85789c3c86e16fe8e491",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the company's bruised financials.",
                "category": "company",
                "datetime": 1785771878,
                "headline": "Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant"
              },
              {
                "id": 141099543,
                "url": "https://finnhub.io/api/news?id=efbb6286c011dfbe2cb89cbed78750eeb1119ac1d173ab9221b91d260d6e74a1",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1785767701,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 139932823,
                "url": "https://finnhub.io/api/news?id=d08bec2c986ad84c660e7b6cf19364768850055926e7b5b30c3a247ae5aa2883",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "",
                "category": "company",
                "datetime": 1785766428,
                "headline": "Intuitive Surgical shares are trading higher after the company reported better-than-expected Q1 financial results."
              },
              {
                "id": 141087290,
                "url": "https://finnhub.io/api/news?id=045477e16e105dc48736eeeb285820cf141a6fe71274b46f3bf8259ace4dccd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q2 CY2026, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785590157,
                "headline": "BSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook"
              },
              {
                "id": 141086201,
                "url": "https://finnhub.io/api/news?id=4a789763508faeb10450120a1ba58283d9561c73f339977e72798c9c67593dc8",
                "image": "",
                "source": "Fintel",
                "related": "BSX",
                "summary": "",
                "category": "company",
                "datetime": 1785575794,
                "headline": "Argus Research Downgrades Boston Scientific (BSX)"
              },
              {
                "id": 141078060,
                "url": "https://finnhub.io/api/news?id=82cc1ba9c7bd8f71b6e536a32c9e3fcd340556defa4cd9b190e0477169aefb1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1785505577,
                "headline": "Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141077306,
                "url": "https://finnhub.io/api/news?id=bebb78be3cf253bac003b07b4ffe9c663ca8a9f604aac5d2ac6c9f813eb5a18d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.",
                "category": "company",
                "datetime": 1785498704,
                "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Blackstone Mortgage, Boston Scientific, Edison International, Ford, GoDaddy, International Paper, Roblox, Saia, and More"
              },
              {
                "id": 141082202,
                "url": "https://finnhub.io/api/news?id=7e2cf3d26428bc0d1d047612f26e46e3b42ae123b15e974071eefbdf76c37295",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Argus Research  analyst David Toung   downgrades Boston Scientific (NYSE:BSX) from Buy to Hold.",
                "category": "company",
                "datetime": 1785482800,
                "headline": "Argus Research Downgrades Boston Scientific to Hold"
              },
              {
                "id": 141070047,
                "url": "https://finnhub.io/api/news?id=a9e668da6a1417971892877325988f0dd0b99d65b5740f274ba26f108cd8cd9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.",
                "category": "company",
                "datetime": 1785441900,
                "headline": "Penumbra, Inc. Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141082203,
                "url": "https://finnhub.io/api/news?id=dbebd8a1893cc0617bc6488934377ca9e6d18ab3bc37812c7b8fe964bafcf3d5",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "UBS  analyst Patrick Wood   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $74 to $67.",
                "category": "company",
                "datetime": 1785428747,
                "headline": "UBS Maintains Buy on Boston Scientific, Lowers Price Target to $67"
              },
              {
                "id": 141068465,
                "url": "https://finnhub.io/api/news?id=9bd7c200527a8e2f9b9c5db31db52e03035e8b8a07c2f5d5e2d8ae0557789bb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year",
                "category": "company",
                "datetime": 1785427034,
                "headline": "Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says"
              },
              {
                "id": 141082204,
                "url": "https://finnhub.io/api/news?id=d41be08cda555fba9936d26a73a7051e06a346e346b21763e1aae7148ab52c00",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $70 to $61.",
                "category": "company",
                "datetime": 1785421104,
                "headline": "Citigroup Maintains Buy on Boston Scientific, Lowers Price Target to $61"
              },
              {
                "id": 141066922,
                "url": "https://finnhub.io/api/news?id=30752d848b77e458c7884e832a6fb8200acd3dbb6f82462422773ac912884558",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.",
                "category": "company",
                "datetime": 1785420000,
                "headline": "BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure"
              },
              {
                "id": 141082205,
                "url": "https://finnhub.io/api/news?id=2cbf17d20c9ee9ab5542d3ffe47e47e90fe19c20fc9f867726a3e606b112caf0",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "RBC Capital  analyst Kendall Au   maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $70.",
                "category": "company",
                "datetime": 1785418059,
                "headline": "RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $70"
              },
              {
                "id": 141082206,
                "url": "https://finnhub.io/api/news?id=68560833d85d8e4fbc34b1d70891a6fcf2cb8b4c794ec6c64ffc22056b0ce4ad",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "TD Cowen  analyst Joshua Jennings   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $61 to $56.",
                "category": "company",
                "datetime": 1785412021,
                "headline": "TD Cowen Maintains Buy on Boston Scientific, Lowers Price Target to $56"
              },
              {
                "id": 141082207,
                "url": "https://finnhub.io/api/news?id=134de6b264f278c20fc97a1d245c7139321d3848a510bf98ebab2117f9038ae5",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Canaccord Genuity  analyst William Plovanic   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $70 to $66.",
                "category": "company",
                "datetime": 1785411790,
                "headline": "Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $66"
              },
              {
                "id": 141066332,
                "url": "https://finnhub.io/api/news?id=ceabeaa1bfcd74848bf757815134dde35cd76b57172f1cc3c9509ddc85837631",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Truist Securities  analyst Richard Newitter   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $62 to $57.",
                "category": "company",
                "datetime": 1785409710,
                "headline": "Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $57"
              },
              {
                "id": 141068466,
                "url": "https://finnhub.io/api/news?id=cc9883069028f8d68527076de94b144abcb5833259f49342e32cf53351e31046",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.",
                "category": "company",
                "datetime": 1785408680,
                "headline": "What Are Wall Street Analysts' Target Price for Boston Scientific Stock?"
              },
              {
                "id": 141066333,
                "url": "https://finnhub.io/api/news?id=64d02eb26f8d301f0a09edc7ed32d133ac8c8f6bcba4c075cd77bcf9d753c83b",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $65 to $55.",
                "category": "company",
                "datetime": 1785406861,
                "headline": "Evercore ISI Group Maintains Outperform on Boston Scientific, Lowers Price Target to $55"
              },
              {
                "id": 141065787,
                "url": "https://finnhub.io/api/news?id=0dbfdf17ffc0cb133a88588dd1bca5361fd3cd546c494b71cfb5d2dd72b73fe4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432882297/image_1432882297.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Boston Scientific has reset expectations, slashing guidance and acknowledging competitive pressures. Find out why BSX stock is a buy.",
                "category": "company",
                "datetime": 1785405682,
                "headline": "Boston Scientific: Attempting The 2027 Reset"
              },
              {
                "id": 141066334,
                "url": "https://finnhub.io/api/news?id=02f30dfd185acba19b9d10d4897f89ef35bee5be774407bcd9cd780034aefb60",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $55 to $50.",
                "category": "company",
                "datetime": 1785405406,
                "headline": "Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $50"
              },
              {
                "id": 141063997,
                "url": "https://finnhub.io/api/news?id=e3851e74a082057dd9aa26e154ff60a05f46e377427385a9292f413785ce0347",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Analyst fair value for Boston Scientific has shifted from US$75.00 to US$72.25, pointing to a modest reset in price targets. This change lines up with recent research that lowers expectations for Watchman and electrophysiology while still recognizing strengths across the broader portfolio and generally positive ratings. As you read on, you will see how these moving targets, both bullish and bearish, shape the evolving Boston Scientific story and what to watch next. Stay updated as the Fair...",
                "category": "company",
                "datetime": 1785402499,
                "headline": "Boston Scientific (BSX) Stock Sees Modest Fair Value Cut As Watchman Concerns Reset Expectations"
              },
              {
                "id": 141063034,
                "url": "https://finnhub.io/api/news?id=c76697c5c0a58380c0de65a8b48e19bf4268150879484e397dbd3c35e4b6eea1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...",
                "category": "company",
                "datetime": 1785385725,
                "headline": "Boston Scientific (BSX) Is Up 7.1% After Q2 Beat, Recall And Major Restructuring Plan - Has The Bull Case Changed?"
              },
              {
                "id": 141059821,
                "url": "https://finnhub.io/api/news?id=50b8c0ff812d2f80564237e77a08caaf7ee5aff83674ebe03c3902d887297834",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Moby summary of Boston Scientific Corporation's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785362125,
                "headline": "Boston Scientific Corporation Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141058553,
                "url": "https://finnhub.io/api/news?id=049e0667ac38c1bdb506783a563224f7331980aa36cbfdbcd5b33f0e09afe9e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi",
                "category": "company",
                "datetime": 1785355438,
                "headline": "Boston Scientific Q2 Earnings Call Highlights"
              },
              {
                "id": 141056998,
                "url": "https://finnhub.io/api/news?id=a7dcfe2fe96bffadb525443192a34a9ac97e51b8d93183b0230da5d85aa77588",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and",
                "category": "company",
                "datetime": 1785354366,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 141057181,
                "url": "https://finnhub.io/api/news?id=dd903a17dd6bb593b57b27c3d22b17b4e804f6778696ec0c89525d0dc118e720",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.",
                "category": "company",
                "datetime": 1785351843,
                "headline": "Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional ..."
              },
              {
                "id": 141056192,
                "url": "https://finnhub.io/api/news?id=c766f88e616916fe8e40600df5afe7cbf8d7ee2d3376090d27e1bd4192e4fb2e",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1785348302,
                "headline": "Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session."
              },
              {
                "id": 141055665,
                "url": "https://finnhub.io/api/news?id=689226e9857ec7cac1da65efb7e5fb2d018a298a67a1cf8ffa7ff085cefe30ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Healthcare stocks were slightly lower Wednesday afternoon, with the NYSE Healthcare Index down 0.1%",
                "category": "company",
                "datetime": 1785346406,
                "headline": "Sector Update: Healthcare Stocks Edge Lower in Afternoon Trading"
              },
              {
                "id": 141055135,
                "url": "https://finnhub.io/api/news?id=4dc12047b41ce397449a1555482561b53f25523ac38d9977a9ca33d8022dc596",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.",
                "category": "company",
                "datetime": 1785344700,
                "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."
              },
              {
                "id": 141055900,
                "url": "https://finnhub.io/api/news?id=3a1fd910fa3e1a2d3a3669c17c8dbf9fc86f391f098f6a4b78c3414f25327051",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus...",
                "category": "company",
                "datetime": 1785341220,
                "headline": "Boston Scientific beats second quarter expectations, raises full-year outlook"
              },
              {
                "id": 141054320,
                "url": "https://finnhub.io/api/news?id=56478597088739a9ef29ba72345d948806b4209219b8892449b9c357c2985673",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston's tempered 2026 outlook is likely due in part to its recently announced plans to initiate a global restructuring programme.",
                "category": "company",
                "datetime": 1785340295,
                "headline": "Boston Scientific reports positive Q2 results yet opts to trim 2026 outlook"
              },
              {
                "id": 141054047,
                "url": "https://finnhub.io/api/news?id=73d238629d498efdb827745e5672b94a6c855e68df7092faf6295dcac9246948",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c",
                "category": "company",
                "datetime": 1785338822,
                "headline": "Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device"
              },
              {
                "id": 141054322,
                "url": "https://finnhub.io/api/news?id=cf8192083410f5302255e882bbbcfe0c984669f204e3d40254a9269ee695f7c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785335403,
                "headline": "Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141061769,
                "url": "https://finnhub.io/api/news?id=062aa64f16886b6df080820d5dfc89af84239b4a45f18a867d04770c5f84800a",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "BTIG  analyst Marie Thibault   maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $65 to $60.",
                "category": "company",
                "datetime": 1785335280,
                "headline": "BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $60"
              },
              {
                "id": 141053182,
                "url": "https://finnhub.io/api/news?id=1a5f6f8eecfddc754781d5211dbae33b4ca373ffded93226ce2e0035f4790b66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41",
                "category": "company",
                "datetime": 1785330176,
                "headline": "Boston Scientific Q2 2026 earnings: profit forecast cut on Watchman slowdown"
              },
              {
                "id": 141054323,
                "url": "https://finnhub.io/api/news?id=a3aef00cbe41993bf01f0396883fd69b084a50114577f7987ef97535873fe920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.",
                "category": "company",
                "datetime": 1785330060,
                "headline": "Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs"
              },
              {
                "id": 141052519,
                "url": "https://finnhub.io/api/news?id=d12ea2b97a7b8de7d8605f8f43bbe2a535312469ed9993773e3e6f01acd75ef9",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.",
                "category": "company",
                "datetime": 1785328501,
                "headline": "Get insights into the top movers in the S&P500 index of Wednesday's pre-market session."
              },
              {
                "id": 141053183,
                "url": "https://finnhub.io/api/news?id=6d6b65e808e57546e505abf68d625859db130db801549d733a6fec3f8143a9b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The company reported earnings of $0.",
                "category": "company",
                "datetime": 1785328033,
                "headline": "Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts Shares"
              },
              {
                "id": 141053184,
                "url": "https://finnhub.io/api/news?id=ce97b59f060ad8b95f2959cd2b75d32dd94b2eeec0b0f7376a7179667d351683",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) delivered earnings and revenue surprises of +3.61% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785327905,
                "headline": "Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 141054044,
                "url": "https://finnhub.io/api/news?id=44c001b8eb09651befca60290bb06b4467e6a5de6f1f89228a1a7bf643fd5e53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "A busy afternoon of earnings from Meta and Microsoft comes as the Fed is expected to hold rates",
                "category": "company",
                "datetime": 1785327180,
                "headline": "Dow Jones down over 800 points as Trump lashes out ahead of Fed decision"
              },
              {
                "id": 141054640,
                "url": "https://finnhub.io/api/news?id=8b0c7a25f7dfbcf0b87315813d91b2d5f6599e35e023d5d8e7a9f802d7f0256a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (BSX) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsLauren Tengler - Director of Investor...",
                "category": "company",
                "datetime": 1785326595,
                "headline": "Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141052917,
                "url": "https://finnhub.io/api/news?id=c73ec1e45071df7ab6cf027726410cb65ae0a0f6ec8c56db89e4703ca4176140",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The main US stock measures were mostly trending higher in Wednesday's premarket activity as traders",
                "category": "company",
                "datetime": 1785326392,
                "headline": "Stocks Mostly Up Pre-Bell Ahead of Fed Rate Decision, Big Tech Earnings"
              },
              {
                "id": 141055901,
                "url": "https://finnhub.io/api/news?id=587de705b5880896f838b010d6e7960265583fbeb709acf2a7b91ab7d080732c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share forecasts for the second quarter in a row.",
                "category": "company",
                "datetime": 1785326100,
                "headline": "Boston Scientific again cuts 2026 guidance"
              },
              {
                "id": 141051895,
                "url": "https://finnhub.io/api/news?id=e3c22d3b43e4606b1490e9974d204db76695ca49fc89ec8dc2201c7a8e12db00",
                "image": "https://www.chartmill.com/images/uploads/earnings_article_1_defce97180.webp",
                "source": "ChartMill",
                "related": "BSX",
                "summary": "Boston Scientific beat Q2 2026 estimates with $0.86 adjusted EPS (beat 3%) and $5.442B revenue (inline). Shares rose 4.2% pre-market on strong earnings performance.",
                "category": "company",
                "datetime": 1785324135,
                "headline": "Boston Scientific (NYSE:BSX) Tops Q2 2026 Estimates on Adjusted EPS Beat"
              },
              {
                "id": 141052212,
                "url": "https://finnhub.io/api/news?id=00bb7c15e48e58f3ac9b2a3495b2878951f5682677382d2c0f79a23439317f05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Investing.com -- Shares in Boston Scientific rose over 3% in premarket trading Wednesday after the medical device maker reported second-quarter earnings and revenue that topped Wall Street estimates.",
                "category": "company",
                "datetime": 1785323704,
                "headline": "Boston Scientific stock gains as medical device maker tops Q2 forecasts"
              },
              {
                "id": 141061770,
                "url": "https://finnhub.io/api/news?id=6376171615604a98b32c21788089b2c3acd452df932a86e32db140e963129c91",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Sep-16--2019-Fremont--Ca--Usa---Boston.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Boston Scientific beat second-quarter estimates but lowered its 2026 sales and earnings outlook as restructuring costs weighed on guidance.",
                "category": "company",
                "datetime": 1785323543,
                "headline": "Boston Scientific Cuts Forecast on Product Slowdown and Competition"
              },
              {
                "id": 141052213,
                "url": "https://finnhub.io/api/news?id=791fc474bd03c53607709e9659d73f420b282aeef62c2460994ebb44d448bdcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785323485,
                "headline": "Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations"
              },
              {
                "id": 141052214,
                "url": "https://finnhub.io/api/news?id=ef9571db900e34a64ad62da4d488d948e928062f2498676ef159890cde6b9977",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared t",
                "category": "company",
                "datetime": 1785321000,
                "headline": "Boston Scientific announces results for second quarter 2026"
              },
              {
                "id": 141052498,
                "url": "https://finnhub.io/api/news?id=67f13e7dce4a4153cb00fc345b6d20396e901f73d3b9db2613ae57a61a2c4e48",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "2026-07-29. The following slide deck was published by Boston Scientific Corporation in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785313881,
                "headline": "Boston Scientific Corporation 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141061771,
                "url": "https://finnhub.io/api/news?id=0b0e5bb6f85dba4166ad9341db23c3d483384259c7657a5a4395ee59ac409923",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) is looking for Q3 Adj EPS of $0.80-$0.82 vs $0.83 analyst estimate. sees sales of $5.217 billion-$5.318 billion vs $5.358 billion analyst estimate.",
                "category": "company",
                "datetime": 1785306845,
                "headline": "Boston Scientific Sees Q3 Adj EPS $0.80-$0.82 vs $0.83 Est; Sees Sales $5.217B-$5.318B vs $5.358B Est"
              },
              {
                "id": 141061772,
                "url": "https://finnhub.io/api/news?id=9354cf03c8f740ec3fa36924b2b8a93fb2c421a6cd831fbd62e996905751f30c",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36 analyst estimate. Lowers FY2026 sales outlook from $21.479 billion-$21.780 billion to $21.178 billion-$21.379 billion",
                "category": "company",
                "datetime": 1785306766,
                "headline": "Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36 Est; Lowers FY2026 Sales Guidance from $21.479B-$21.780B to $21.178B-$21.379B vs $21.562B Est"
              },
              {
                "id": 141061773,
                "url": "https://finnhub.io/api/news?id=053368942849755adaa19e830066681e0d38291a8085f795290dffe25d275935",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.83 by 3.61 percent. This is a 14.67 percent increase over earnings of $0.75 per share from the",
                "category": "company",
                "datetime": 1785306722,
                "headline": "Boston Scientific Q2 Adj. EPS $0.86 Beats $0.83 Estimate, Sales $5.442B Beat $5.361B Estimate"
              },
              {
                "id": 141045528,
                "url": "https://finnhub.io/api/news?id=ad7f745883259fc021a3b634be189425acb7e3cedaa328951b9890dbbb1bb36c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston expects its restructuring plan to cost between $700m and $800m and be completed by the end of 2029.",
                "category": "company",
                "datetime": 1785256447,
                "headline": "Boston Scientific expects headcount reductions amid restructuring initiative"
              },
              {
                "id": 141041757,
                "url": "https://finnhub.io/api/news?id=e608a003141f5e728800fd2bcdd8587566b862645fcbc91a95de09a83cfd0975",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Cloud-based AI algorithm supports implantable cardiac monitors from all major manufacturers, reducing false-positive alerts by up to 76% while maintaining high sensitivity for true events CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Implicity, a leader in remote patient monitoring and cardiac data management solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation ILR ECG Analyzer, marking Implicity's third FDA cleara",
                "category": "company",
                "datetime": 1785239100,
                "headline": "Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance"
              },
              {
                "id": 141041716,
                "url": "https://finnhub.io/api/news?id=2a86e4b8fd92ac62a83ec851d35f1e19f535387b356654c5c93fd6c2bfdd1cb0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.",
                "category": "company",
                "datetime": 1785238969,
                "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More"
              },
              {
                "id": 141043888,
                "url": "https://finnhub.io/api/news?id=a4eacf80b0bec7cbeb6b08cfd1d10ae96ce0f50812ce33b715c76e124ae4557f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The plan involves transferring production lines and cutting jobs, following a slowdown in two of the company’s key product lines.",
                "category": "company",
                "datetime": 1785235982,
                "headline": "Boston Scientific to restructure, taking up to $800M in charges"
              },
              {
                "id": 141041184,
                "url": "https://finnhub.io/api/news?id=a59c44f2f68192da00049ebcdbdc9d8dcf8bd95fb926d1266440b0f62b010d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.",
                "category": "company",
                "datetime": 1785229262,
                "headline": "What To Expect From Boston Scientific’s (BSX) Q2 Earnings"
              },
              {
                "id": 141041557,
                "url": "https://finnhub.io/api/news?id=7d3fe4c0d23f407ac74fb782e56ffe787cecacb6384ae5c0e8ee27f650627233",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259148943/image_2259148943.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "The Silvant Large Cap Growth SMA returned +14.61% (gross)/+13.79% (net) for the quarter compared to the Russell 1000 Growth Index's return of +16.74%. Read more here.",
                "category": "company",
                "datetime": 1785224400,
                "headline": "Virtus Large Cap Growth SMA Q2 2026 Portfolio Update"
              },
              {
                "id": 141045482,
                "url": "https://finnhub.io/api/news?id=cbc8875e129069758ebfd5b5605cda1817a6812470a9ca12da3652e9a217b579",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "https://www.sec.gov/ix?doc=/Archives/edgar/data/885725/000088572526000049/bsx-20260721.htm",
                "category": "company",
                "datetime": 1785168637,
                "headline": "Boston Scientific Approves 2026 Global Restructuring Program; Plan Intends To Cut Headcount; Expects ~$700M - $800M As Pre-Tax Charges; Plan Expected To Reduce Annual Pre-Tax Expenses by $500M"
              },
              {
                "id": 141035129,
                "url": "https://finnhub.io/api/news?id=c92ef4a473af545abf93085c0feb833d345113b7ee6e12a65912c65c41f0d0ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.",
                "category": "company",
                "datetime": 1785167220,
                "headline": "J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?"
              },
              {
                "id": 141045483,
                "url": "https://finnhub.io/api/news?id=7700dd908c3d15ced2f5514f0ac9ae15f312832be50483ca63d40f401f379b1c",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "https://news.bloomberglaw.com/health-law-and-business/boston-scientific-gets-42-million-stent-patent-verdict-reversed",
                "category": "company",
                "datetime": 1785154672,
                "headline": "'Boston Scientific Gets $42 Million Stent Patent Verdict Reversed' - Bloomberg"
              },
              {
                "id": 141045484,
                "url": "https://finnhub.io/api/news?id=2ef5dd24476682cde144ac7144ab997d8c5c0682096fd45ea0ff6a07814cf052",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.23% on an annualized basis producing an average annual return of 13.77%. Currently, Boston Scientific has a market capitalization of",
                "category": "company",
                "datetime": 1785149153,
                "headline": "Here's How Much $100 Invested In Boston Scientific 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 141033415,
                "url": "https://finnhub.io/api/news?id=2bbae2db157ab89f4609282fcd67c4cb0b54036c57251be7c12a1e653e5bf49c",
                "image": "",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "Oppenheimer  analyst Suraj Kalia   maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $90 to $85.",
                "category": "company",
                "datetime": 1785143900,
                "headline": "Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $85"
              },
              {
                "id": 141006570,
                "url": "https://finnhub.io/api/news?id=8f3ed990bac78bbe2aab4028c06f246d6f29d4c4e20085b579d57ee033147671",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.",
                "category": "company",
                "datetime": 1784898904,
                "headline": "Boston Scientific (BSX) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures"
              },
              {
                "id": 141005373,
                "url": "https://finnhub.io/api/news?id=b36b031e7ee377bc4138167b006d1828b02fd77c1e500f55b43a05f249614da2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.",
                "category": "company",
                "datetime": 1784895900,
                "headline": "6 Medical-Device Stocks to Buy After a Massive Selloff"
              },
              {
                "id": 141003245,
                "url": "https://finnhub.io/api/news?id=2ebd8eda6820cc2c6f0a825f7bed40d44a97ae7a597344157a7a0eb81e98b72d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.",
                "category": "company",
                "datetime": 1784871000,
                "headline": "Medical-Device Stocks Are in the Bargain Bin. 6 to Buy."
              },
              {
                "id": 141002553,
                "url": "https://finnhub.io/api/news?id=3fb33829d4e318309e8e056c3e67b301a229a4790f57ba382a422d50ecc0c59d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/915092842/image_915092842.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "For months I've had an uneasy feeling about the sustainability of this great bull run.",
                "category": "company",
                "datetime": 1784854800,
                "headline": "Have We Entered A Stealth Bear Market?"
              },
              {
                "id": 140996690,
                "url": "https://finnhub.io/api/news?id=85af9e8893acc6773c696c8ffbce2fa38f27f38ee6fd643adf77b9f3130959f1",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BSX",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1784813736,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140991408,
                "url": "https://finnhub.io/api/news?id=ba0381e681b8e226e29647244ebeaa94d248c219e56ba8f2164c63dbfd7d6836",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (NYSE:BSX) has enrolled the first patients in the global FARADIGM trial. The study evaluates the Faraflex pulsed field ablation device for the treatment of atrial fibrillation. This milestone marks the formal start of large scale clinical testing for the Faraflex system. Boston Scientific is a major player in cardiac rhythm and electrophysiology devices, and the FARADIGM trial adds another clinical program to that portfolio. Atrial fibrillation treatments have been an area...",
                "category": "company",
                "datetime": 1784790803,
                "headline": "Boston Scientific (BSX) Enrolls First Patients In Global Faraflex AFib Trial"
              },
              {
                "id": 140983262,
                "url": "https://finnhub.io/api/news?id=4804a7123f414ba8d9f37bc3eaec1a74f90e38ae8851204e95e2a8758f3a314c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific stock has had a tough run over the past year, yet the valuation checks still lean supportive, setting up a clear tension between recent share price weakness and what the broader metrics suggest about value. Boston Scientific shares are down about 58.1% over the past year, which sharply resets expectations around what investors are willing to pay for the business. Upcoming earnings and progress integrating recent device acquisitions may support sentiment, while ongoing Class...",
                "category": "company",
                "datetime": 1784733132,
                "headline": "Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump"
              },
              {
                "id": 140982003,
                "url": "https://finnhub.io/api/news?id=8cf71b138d3761650389a711f4dda8648ffbcf5ba464e7dcc92e0740d0fb8194",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and CRE Pro Wireguided gastrointestinal devices, tied to potential sterile pouch breaches across widely distributed product lots. With more than 81,000 units cited in individual recall notices and a worldwide distribution footprint, the situation brings product quality controls, potential regulatory implications and timing before the upcoming earnings...",
                "category": "company",
                "datetime": 1784726003,
                "headline": "Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued"
              },
              {
                "id": 140977765,
                "url": "https://finnhub.io/api/news?id=a31c7dd1d6baca0b0d12b261041c20bd387935179f3276e4a502f27b75b1c34d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Boston Scientific (BSX) reached $43.19 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.",
                "category": "company",
                "datetime": 1784671204,
                "headline": "Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 140974912,
                "url": "https://finnhub.io/api/news?id=bbdead80568b813174817288369cedcdbc1558cbe69a3fa5d808987e69a9b82d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.",
                "category": "company",
                "datetime": 1784660157,
                "headline": "Why BSX Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 140971693,
                "url": "https://finnhub.io/api/news?id=a44cd51e74b74d214cb2c38b67dfde3d97fb31250c3bd9176d83a7e1f30be12f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.",
                "category": "company",
                "datetime": 1784641620,
                "headline": "Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?"
              },
              {
                "id": 140971260,
                "url": "https://finnhub.io/api/news?id=2344fdefceebd65f91360aefc32faaadaf2f4e51f7cfcf30b5de5f02d820a46c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253086812/image_2253086812.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BSX",
                "summary": "Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Read more here.",
                "category": "company",
                "datetime": 1784633100,
                "headline": "Artisan Value Fund Q2 2026 Portfolio Update"
              },
              {
                "id": 140962070,
                "url": "https://finnhub.io/api/news?id=1ebbbe08a8b80b830d991a30a1fcb84f31b2ff57e24f8f5911a74c91ef024e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "ASI DATAMYTE, Inc. (\"DATAMYTE\"), a leading provider of production and quality management solutions serving over 1000 manufacturers including Ford, Boston Scientific, Northrop Grumman, CS Wind, Stellantis, Boeing, Tesla, Gillette, Borg Warner, Cabinetworks Group, Foxconn, Pepsico, GM, and more, announced today that it has achieved ISO/IEC 27001:2022 certification for the information security management system (ISMS) supporting Digital Clipboard, its cloud-based, no-code manufacturing workflow pla",
                "category": "company",
                "datetime": 1784567340,
                "headline": "DATAMYTE Achieves ISO/IEC 27001:2022 Certification for Digital Clipboard, Its No-Code Manufacturing Workflow Platform"
              },
              {
                "id": 140970643,
                "url": "https://finnhub.io/api/news?id=6977fec31dc682ec66e7e5f7a0adbda1a62913b9c702ae32e5158f8563006d3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.",
                "category": "company",
                "datetime": 1784554800,
                "headline": "3 Medical Device Stocks Giving Investors a Different Healthcare Play"
              },
              {
                "id": 140951754,
                "url": "https://finnhub.io/api/news?id=6ba6159069d25ba45726b5c1d6ff6db30fd98807f5de1cad5c47a5f9d5cff570",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BSX",
                "summary": "Intuitive Surgical shares fell about 10% after Q2 2026 revenue rose 19% but guidance for da Vinci procedure growth wasn't raised, pushing ISRG below its 200-week moving average.",
                "category": "company",
                "datetime": 1784376900,
                "headline": "Why Intuitive Surgical’s Strong Quarter Still Spooked Investors"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 113,
            "discarded_article_count": 83
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.4,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日4日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 8,
              "vol_ref": 18532826.666666668,
              "down_days": 1,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 17640260,
              "avg_vol_20": 20289085,
              "avg_vol_30": 18532826.666666668,
              "range_pct_10": 0.11452463542679375,
              "range_pct_20": 0.20396655648454215,
              "range_pct_30": 0.20979972778533929,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 4,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.951838611415276,
              "dist_to_20d_high": 0.029439516889979284,
              "down_shrink_days": 1,
              "breakout_level_20d": 52.99,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5458759962928641
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.539568345323741,
              "turnoverUsdM": 663.6340509099999,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BSX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 47.7892,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 7.1,
            "take_profit_price": 54.3426,
            "target_multiplier": 1.6,
            "technical_strength": 1.5,
            "take_profit_percent": 5.7
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 7.079136690647482,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 1.8204,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.54
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 95.37
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1595
    },
    "kdj": {
      "d": 86.96,
      "j": 74.62,
      "k": 82.84,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 72.7
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 8,
      "trend": "資金入貨",
      "value": -129821437,
      "recentSlope": 8852966.3,
      "previousSlope": 5643010
    },
    "rsi": 79.87,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 49.7201,
      "position": "SAR喺價下",
      "distancePct": 3.32,
      "previousTrend": "上升"
    },
    "ma50": 46.2632,
    "macd": {
      "macd": 1.6393380781860998,
      "trend": "強烈看漲",
      "signal": 1.1349889875897394,
      "histogram": 0.5043490905963603
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 47.3107,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 17
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.64,
      "score": 2,
      "avgVolume": 20277772,
      "currentVolume": 12903637
    },
    "derived": {
      "ma20": 47.811,
      "ma50": 46.2632,
      "prevClose": 51.83,
      "avgVolume10": 16892624,
      "avgVolume20": 20277772,
      "changePercent": -0.77,
      "avgVolumeForScore": 20277772
    },
    "ma_cross": {
      "ma20": 47.811,
      "ma50": 46.2632,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 47.428,
      "prevMa50": 46.2116,
      "spreadPct": 3.35,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 41.9193,
      "upper": 53.7027,
      "position": "上半部"
    },
    "rsi_short": 86.3,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.64
    }
  }
}

{
  "close": 51.43,
  "volume": 12903637,
  "changePercent": -0.77
}